310 related articles for article (PubMed ID: 33057635)
21. Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
Hong M; Hao S; Patel KP; Kantarjian HM; Garcia-Manero G; Yin CC; Medeiros LJ; Lin P; Lu X
Cancer Genet; 2016 May; 209(5):205-14. PubMed ID: 27134073
[TBL] [Abstract][Full Text] [Related]
22. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of TP53 mutations and single nucleotide polymorphisms in acute myeloid leukemia: a case series and literature review.
Zeichner SB; Alghamdi S; Elhammady G; Poppiti RJ
Asian Pac J Cancer Prev; 2014; 15(4):1603-9. PubMed ID: 24641375
[TBL] [Abstract][Full Text] [Related]
24. Transcriptional profiling demonstrates altered characteristics of CD8
Abolhalaj M; Sincic V; Lilljebjörn H; Sandén C; Aab A; Hägerbrand K; Ellmark P; Borrebaeck CAK; Fioretos T; Lundberg K
Cancer Med; 2022 Aug; 11(15):3023-3032. PubMed ID: 35297213
[TBL] [Abstract][Full Text] [Related]
25. Clinical characteristics and overall survival among acute myeloid leukemia patients with TP53 gene mutation or chromosome 17p deletion.
Daver NG; Iqbal S; Huang J; Renard C; Lin J; Pan Y; Williamson M; Ramsingh G
Am J Hematol; 2023 Aug; 98(8):1176-1184. PubMed ID: 37139921
[TBL] [Abstract][Full Text] [Related]
26. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.
Hou HA; Chou WC; Kuo YY; Liu CY; Lin LI; Tseng MH; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Huang SY; Ko BS; Hsu SC; Chen CY; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
Blood Cancer J; 2015 Jul; 5(7):e331. PubMed ID: 26230955
[TBL] [Abstract][Full Text] [Related]
27. A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates.
Chichili GR; Huang L; Li H; Burke S; He L; Tang Q; Jin L; Gorlatov S; Ciccarone V; Chen F; Koenig S; Shannon M; Alderson R; Moore PA; Johnson S; Bonvini E
Sci Transl Med; 2015 May; 7(289):289ra82. PubMed ID: 26019218
[TBL] [Abstract][Full Text] [Related]
28. Novel high-risk acute myeloid leukemia subgroup with ERG amplification and Biallelic loss of TP53.
Schandl CA; Mazzoni S; Znoyko I; Nahhas GJ; Chung D; Ding Y; Hess B; Wolff DJ
Cancer Genet; 2023 Apr; 272-273():23-28. PubMed ID: 36657266
[TBL] [Abstract][Full Text] [Related]
29. The role of TP53 in acute myeloid leukemia: Challenges and opportunities.
Barbosa K; Li S; Adams PD; Deshpande AJ
Genes Chromosomes Cancer; 2019 Dec; 58(12):875-888. PubMed ID: 31393631
[TBL] [Abstract][Full Text] [Related]
30.
George B; Kantarjian H; Baran N; Krocker JD; Rios A
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639121
[TBL] [Abstract][Full Text] [Related]
31. AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy.
Yan B; Claxton D; Huang S; Qiu Y
Exp Hematol; 2020 Jul; 87():13-19. PubMed ID: 32569759
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML.
Man CH; Lam W; Dang CC; Zeng XY; Zheng LC; Chan NN; Ng KL; Chan KC; Kwok TH; Ng TC; Leung WY; Huen MS; Wong CC; So CWE; Dou Z; Goyama S; Bray MR; Mak TW; Leung AY
Blood; 2023 Dec; 142(23):2002-2015. PubMed ID: 37738460
[TBL] [Abstract][Full Text] [Related]
33. Flotetuzumab as a salvage immunotherapy in advanced CD123-positive hematological malignancies, a phase 1 pilot study.
Aldoss I; Zhang J; Robbins M; Song J; Al Malki MM; Otoukesh S; Sandhu K; Agrawal V; Herrera AF; Popplewell LL; Ghoda L; Stein A; Marcucci G; Forman S; Pullarkat V
Leuk Lymphoma; 2024 Apr; ():1-9. PubMed ID: 38629176
[TBL] [Abstract][Full Text] [Related]
34. Current status and new treatment approaches in TP53 mutated AML.
Hunter AM; Sallman DA
Best Pract Res Clin Haematol; 2019 Jun; 32(2):134-144. PubMed ID: 31203995
[TBL] [Abstract][Full Text] [Related]
35. TP53 signal pathway confers potential therapy target in acute myeloid leukemia.
Zhu G; Cai J; Zhong H
Eur J Haematol; 2023 May; 110(5):480-489. PubMed ID: 36692074
[TBL] [Abstract][Full Text] [Related]
36. TP53 mutations in older adults with acute myeloid leukemia.
Yanada M; Yamamoto Y; Iba S; Okamoto A; Inaguma Y; Tokuda M; Morishima S; Kanie T; Mizuta S; Akatsuka Y; Okamoto M; Emi N
Int J Hematol; 2016 Apr; 103(4):429-35. PubMed ID: 26781615
[TBL] [Abstract][Full Text] [Related]
37. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.
Stirewalt DL; Kopecky KJ; Meshinchi S; Appelbaum FR; Slovak ML; Willman CL; Radich JP
Blood; 2001 Jun; 97(11):3589-95. PubMed ID: 11369655
[TBL] [Abstract][Full Text] [Related]
38. Integrated Pharmacokinetic/Pharmacodynamic Model of a Bispecific CD3xCD123 DART Molecule in Nonhuman Primates: Evaluation of Activity and Impact of Immunogenicity.
Campagne O; Delmas A; Fouliard S; Chenel M; Chichili GR; Li H; Alderson R; Scherrmann JM; Mager DE
Clin Cancer Res; 2018 Jun; 24(11):2631-2641. PubMed ID: 29463552
[No Abstract] [Full Text] [Related]
39. [The study of expression and prognostic value of CD123 in acute myeloid leukemia bone marrow blasts].
Yue WQ; Tang GS; Liu M; Cheng H; Ding J; Wang T; Wang JM; Hu XX; Zhang WP; Chen L; Yang JM
Zhonghua Xue Ye Xue Za Zhi; 2017 Oct; 38(10):876-882. PubMed ID: 29166741
[No Abstract] [Full Text] [Related]
40. Activating STING1-dependent immune signaling in
Kogan AA; Topper MJ; Dellomo AJ; Stojanovic L; McLaughlin LJ; Creed TM; Eberly CL; Kingsbury TJ; Baer MR; Kessler MD; Baylin SB; Rassool FV
Proc Natl Acad Sci U S A; 2022 Jul; 119(27):e2123227119. PubMed ID: 35759659
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
